Therapies, Rx Concept & Clinical End-point

• Disease Outcome: Loss of cementum --> tooth loss
• Examples of current therapies: Scaling/root planing, surgery, CR minocycline-HCL (Arestin®)
• Unmet Need: Current approaches do not repair damage predictably (a)
• Target: ENPP1 Enzyme (regulates mineralization)
• Desired Biological Process: Neocementogenesis
• Intervention: Local delivery of ENPP1 antagonist to disease site (b)
• Clinical Endpoint: Reduction in detectable periodontal disease; measurable repair (c)
• Current Therapies: Cost and Sales
  • Cost to Treat: $2K-$30K (visits, treatments, surgery)
  • Sales of Arestin®: $143M Annual Sales
  • US Patient Population: 65M Adults
• Validity of Therapeutic Hypothesis:
  • Human: ENPP1 loss -> Hypercementosis (d)
  • Mouse: Mutant ENPP1 -> Hypercementosis (e)  
  • Mouse: Enpp1-Fc -> reduces cementum (f)
• Therapeutic/Regulatory Approach:
  • CR small molecule antagonists of ENPP1
  • Formulated and delivered as per Arestin®

• Innovators:

  • Braddock (Yale)

  • Somerman (NIH NIAMS)

• IP: Patent Pending